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Endometriosis is a benign gynecological disease. Cyclooxygenase (COX)-2 and aromatase proteins 19 
have been shown to be overexpressed in eutopic endometrium from women suffering from this 20 
disease compared to disease-free women. Furthermore, inhibiting these molecules individually was 21 
demonstrated to have antiproliferative and proapoptotic effects both in vitro and in vivo in several 22 
models. In this study, the effect of combining celecoxib, a selective COX-2 inhibitor, and anastrozole, 23 
an aromatase inhibitor, on the implantation and growth of endometriotic like lesions in a murine 24 
model of endometriosis was evaluated. Endometriosis was surgically induced in female BALB/c 25 
mice. After 28 days of treatment with celecoxib, anastrozole or their combination, animals were 26 
sacrificed and lesions were counted, measured, excised and fixed. Immunohistochemistry  27 
for proliferating cell nuclear antigen and CD34 were performed for assessment of cell proliferation 28 
and vascularization. TdT-mediated dUTP Nick-End Labelling technique was performed for apoptosis 29 
evaluation. Celecoxib was the only treatment to significantly reduce the number of lesions established 30 
per mouse, their size and vascularized area. In addition, cell proliferation was significantly diminished 31 
and apoptosis was significantly enhanced by both individual treatments. When the therapies were 32 
combined they reversed their effects. These results confirm that celecoxib and anastrozole separately 33 
decrease endometriotic growth, but when combined they might have antagonizing effects. 34 
35 




Endometriosis is a benign disease that is characterized by the presence of endometrial tissue outside 37 
the uterine cavity where it proliferates and forms new blood vessels essential for its further 38 
development (Lousse et al. 2012). As an estrogen dependent disease, treatments available up to date, 39 
aim mainly at reducing estrogen levels (Ozkan et al. 2008). Since endometriosis affects women in 40 
reproductive age and given that current available treatments mostly impede ovulation (Rocha et al. 41 
2012), it is the goal of recent research to find alternatives to the existing treatments reducing the side 42 
effects of those now accessible. 43 
We and others have studied the involvement of cyclooxygenase (COX)-2 in this pathology 44 
(Matsuzaki et al. 2004, Banu et al. 2008, Olivares et al. 2008, Olivares et al. 2011), which has been 45 
described to be overexpressed not only in eutopic and ectopic endometrium from endometriosis 46 
patients (Ota et al. 2001, Fagotti et al. 2004), but also in a wide variety of cancers (Mendes et al. 47 
2009, Ghosh et al. 2010, Wang et al. 2010). Selective COX-2 inhibitors are a special class of 48 
nonsteroidal antiinflammatory drugs (NSAIDs) that were developed to treat pain and inflammation 49 
without inhibiting COX-1, thus sparing the gastrointestinal system (Wadman 2007). The COXs are 50 
the enzymes responsible for the synthesis of pain mediators including prostaglandins (PGs). 51 
Particularly, high concentration of PGE2 has been found in the peritoneal fluid of patients with 52 
endometriosis, primarily provided by activated macrophages and the endometriotic lesions (Wu et al. 53 
2010). Our group has demonstrated that selective inhibition of COX-2 activity with celecoxib reduces 54 
the proliferation rate of endometrial epithelial cells as well as it augments their apoptosis levels both 55 
in vitro and in vivo (Olivares et al. 2008, Olivares et al. 2011). Similar results were obtained by other 56 
investigators demonstrating that the inhibition of COX-2 activity has antiproliferative, proapoptotic 57 
and antiangiogenic effects in several in vivo and in vitro cancer models (Gupta et al. 2004, Basu et al. 58 
2005, Dandekar et al. 2005, Barnes et al. 2007) and in other models of endometriosis (Dogan et al. 59 
2004, Laschke et al. 2007, Machado et al. 2010). Moreover, a COX-2 inhibitor has been used in a 60 
pilot study evaluating pain response in endometriosis patients with good results (Cobellis et al. 2004). 61 
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Similarly, aromatase has also been found to be overexpressed in endometriosis with higher protein 62 
and mRNA levels in eutopic endometrium from patients compared to control women as well as in 63 
ectopic endometrium (Bulun et al. 1997, Bulun et al. 2002, Kyama et al. 2008). In this sense, two 64 
aromatase inhibitors, letrozole and anastrozole, have also been tested in vitro and in vivo in our 65 
laboratory and demonstrated to have antiproliferative and proapoptotic effects (Meresman et al. 2005, 66 
Bilotas et al. 2010). 67 
COX-2 is overexpressed in some malignancies including carcinoma of the breast. COX-2 mRNA and 68 
protein levels have been found to correlate with aromatase levels within human breast cancer tissue. 69 
The current understanding of the role of COX-2 in breast cancer suggests that COX-2 inhibitors may 70 
have a role in chemoprevention which is based in part on the generic issues of antiangiogenesis and 71 
proapoptotic processes, and in part on a tissue-specific inhibition of estrogen synthesis (Davies et al. 72 
2002). It has been reported that celecoxib induces a marked inhibition of aromatase protein 73 
expression, assessed by western blot, in human breast cancer cell lines (Bocca et al. 2011). In 74 
addition, treatment with COX-2 siRNAs resulted in suppression of the aromatase gene CYP19 in 75 
breast cancer cells (Brueggemeier et al. 2007). In another experimental model, Sirianni et al. reported 76 
that inhibition of COX-2 downregulates aromatase activity and decreases proliferation of Leydig 77 
tumor cells (Sirianni et al. 2009). In addition, previous studies had shown that aromatase and COX-2 78 
simultaneous inhibition might have additive or even synergic effects (Bundred & Barnes 2005, Ebert 79 
et al. 2005, Chow et al. 2008, Dirix et al. 2008, Falandry et al. 2009). 80 
Furthermore, a feed forward loop has been described between aromatase and PGE2 in endometriosis. 81 
Aromatase synthesizes estrogens, which in turn stimulate the production of PGE2 via COX-2, and 82 
PGE2 stimulates aromatase activity (Bulun et al. 2002). This describes a perfect circle in this system 83 
in which high expression of aromatase will produce high concentrations of estrogens, which will 84 
stimulate COX-2 activity producing high concentrations of PGE2, stimulating again aromatase. 85 
Considering all these data and in sight of the feed forward loop established between these molecules 86 
in endometriosis, we decided to investigate the effect of combining a COX-2 inhibitor with an 87 
aromatase inhibitor, celecoxib and anastrozole respectively, in a murine model of endometriosis. 88 
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For this purpose we treated mice with induced endometriotic like lesions with anastrozole, celecoxib 89 
or both drugs combined, during a four week period and studied their effects on the development of the 90 
disease and on cell proliferation, apoptosis and vascularization within the lesions. 91 
 92 
Results 93 
Celecoxib inhibits the establishment and growth of endometriotic like lesions 94 
After four weeks of treatment with anastrozole, celecoxib or their combination, animals were 95 
sacrificed and the abdominal cavity was explored to localize and measure the lesions developed. 96 
Figure 1 shows the results obtained for the number of lesions established, according to the treatment 97 
the animals received, as well as the volume of those developed. 98 
When mice received celecoxib as the only treatment, not only the lesions established diminished 99 
compared to the control group (p<0.05; Figure 1A), but also the size of those established and 100 
developed was significantly smaller (p<0.01 vs. Control; Figure 1B). However, when animals 101 
received either anastrozole alone or combined with celecoxib, the number of lesions established as 102 
well as their size did not differ from those of the control group.  103 
The COX-2 and aromatase inhibitors affect endometriotic like lesion development 104 
Developed endometriotic like lesions, were excised and fixed for cell proliferation, apoptosis and 105 
vascularization evaluation. Cell proliferation in the epithelial fraction of the lesions was significantly 106 
diminished compared to the control group when animals were treated with celecoxib or anastrozole 107 
separately (p<0.05 for both groups vs. Control); when the treatments were combined, cell 108 
proliferation within the lesions as assessed by PCNA immunohistochemistry, was similar to the 109 
control group (p>0.05). The results are displayed in Figure 2A. 110 
Accordingly, the number of apoptotic epithelial cells was quantified by the TUNEL technique and the 111 
results showed that the combination of the compounds had no effect on cell death where as the 112 
administration of either of them alone significantly enhanced TUNEL positive cells (p<0.05 for 113 
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Anastrozole or Celecoxib vs. Control; p>0.05 for Anastrozole+Celecoxib vs. Control). Results are 114 
displayed in Figure 2B. 115 
When vascular density was assessed within the endometriotic like lesions by immunohistochemistry 116 
of CD34, only the treatment of celecoxib administered on its own showed an inhibitory effect (p<0.05 117 
vs. Control). The aromatase inhibitor alone or in combination with the COX-2 inhibitor, had no effect 118 
on vascular density compared to the control group (p>0.05) (Figure 3). 119 
 120 
COX-2 immunostaining would be enhanced by celecoxib and inhibited by anastrozole 121 
COX-2 protein expression was evaluated in a semiquantitave fashion on developed endometriotic like 122 
lesions after treatment with celecoxib, anastrozole of their combination. When animals received 123 
celecoxib alone, COX-2 immunoreactivity was apparently stimulated while anastrozole seemed to 124 
inhibit it, in both cases, compared to the control group. When the compounds were administered in 125 
combination, the immunostaining of COX-2 was comparable to that in the lesions from control mice. 126 
However, there was no statistical significance in the changes observed. In all cases, and as reported 127 
earlier (Hayes & Rock 2002), immunoreactivity of COX-2 was evident both in the epithelial and 128 
stromal fraction, but higher in the epithelial one. Results are shown in Figure 4. 129 
 130 
Discussion 131 
Endometriosis affects a large number of women all over the world and great efforts are being done by 132 
researchers to give better and longer lasting answers to patients. Treatment for endometriosis is 133 
usually performed with surgery and/or medications. Up to date treatment options are poor and do not 134 
really cure this disease; they aim mainly at reducing pain and endometriotic growth. Nevertheless, the 135 
high recurrence rate of this illness is one of the most challenging problems we face nowadays. In this 136 
sense, investigations are focusing on finding new and more effective alternatives for patients. 137 
In the present study, and taking into account previous results obtained in our laboratory (Bilotas et al. 138 
2010, Olivares et al. 2011) and earlier promising results obtained in cancer (Chow et al. 2008, 139 
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Falandry et al. 2009), we decided to combine two inhibitors: of COX-2 and aromatase. Already some 140 
years ago, Ebert and coworkers reviewed the importance of aiming at these molecules given the 141 
abnormalities present within the eutopic and ectopic endometrium of endometriosis patients (Ebert et 142 
al. 2005) and acknowledging the positive feedback loop present between these molecules (Bulun et al. 143 
2002). 144 
Indeed, few studies had been conducted in breast cancer patients combining exemestane, an aromatase 145 
inhibitor, with celecoxib with somewhat inconclusive results. While some authors suggested that the 146 
addition of celecoxib to exemestane treatment might have promising benefits (Chow et al. 2008, 147 
Falandry et al. 2009), others did not find a beneficial effect from this combination (Dirix et al. 2008). 148 
Our first results showed that celecoxib was the only treatment capable of reducing not only the size of 149 
established lesions, but also the number of lesions established. We had already seen this strong 150 
inhibitory effect of celecoxib in a previous work; at that time we had combined the treatment of 151 
celecoxib with a PPARγ agonist, rosiglitazone, obtaining no additional benefit with this combination 152 
(Olivares et al. 2011). In the present study, the treatment with the aromatase inhibitor and the 153 
combination of both inhibitors did not reduce the number of lesions established nor their size 154 
compared to the control animals. 155 
Even though aromatase and COX-2 inhibition had been postulated to have additive or even synergic 156 
effects in breast cancer (Goss & Strasser-Weippl 2004, Chow et al. 2008) some authors have not 157 
found a clear beneficial effect from this combination (Dirix et al. 2008, Falandry et al. 2009). The 158 
results we are presenting are more in agreement with the latter. 159 
We then investigated the rate of cell proliferation and apoptosis in the lesions developed in all groups. 160 
We observed that cell proliferation in the epithelial fraction of the lesions was significantly 161 
diminished and apoptotic levels were significantly augmented, when animals were treated with 162 
celecoxib or anastrozole separately compared to the control group. It is important to note that even 163 
though the rate of cell proliferation was seen significantly reduced in both of these groups, the 164 
incidence of this decrease was only evidenced macroscopically, in the celecoxib treated animals at the 165 
doses and period of time tested. It was also observed that the administration of anastrozole and 166 
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celecoxib together reversed the effects of either of them alone. Based on these data, we could 167 
speculate that these two compounds, against all odds, were having an antagonistic effect, but further 168 
studies are needed to test this hypothesis.  169 
On the other hand, we only obtained a significant reduction in vascularization with the treatment with 170 
celecoxib alone.  In accordance with our results, treatment with another selective COX-2 inhibitor had 171 
been reported to reduce microvessel density in a SCID mouse model of endometriosis (Ozawa et al. 172 
2006). Furthermore another study in a xenograft model of breast cancer showed that the use of 173 
letrozole, another aromatase inhibitor did not reduce the number of CD31 stained vessels, another 174 
well established vascularization marker (Banerjee et al. 2010). 175 
In contrast, Hull et al. found that nimesulide does not reduce lesion size nor blood vessel development 176 
in an estrogen-supplemented nude mouse model of endometriosis. The authors suggest that the effect 177 
of COX-2 inhibition may be obscured by iatrogenically administered estrogen (Hull et al. 2005). 178 
Nevertheless, other authors have demonstrated COX-2 inhibitors to be effective in ovariectomized 179 
endometriosis mouse models (Efstathiou et al. 2005, Ozawa et al. 2006). 180 
In this work, we have also examined COX-2 immunoreactivity in the developed endometriotic 181 
lesions. Although we did not obtain a statistical significant difference in the changes of COX-2 182 
immunostaining, we observed a tendency to be enhanced when the mice received celecoxib while the 183 
aromatase inhibitor reduced it, both compared to the control group. These results are in agreement 184 
with the reports that have established the existence of a negative feedback loop between the product 185 
from the activity of COX-2 and its protein levels. When the activity of the enzyme is inhibited, this 186 
loop disappears and its protein levels augment (Basu et al. 2005, Ohneseit et al. 2007). On the other 187 
hand, it is known that the product from aromatase activity stimulates mRNA and protein levels, as 188 
well as the activity, of COX-2 (Bulun et al. 2002). With the support from previous reports, the 189 
observed reduction in COX-2 immunostaining after anastrozole treatment is consistent with the 190 
interaction between these two enzymes and their products. Furthermore, even though it has been 191 
reported that the inhibition of COX-2 activity also inhibits the protein expression of aromatase in 192 
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breast cancer cell lines in vitro (Bocca et al. 2011), when exemestane was combined with celecoxib 193 
the protein levels of aromatase were seen unaltered in breast cancer patients (Lustberg et al. 2011). 194 
There are no studies published in the field of endometriosis where the combination of anastrozole 195 
with celecoxib, or any other aromatase or COX-2 inhibitors, has been tested. In breast cancer 196 
research, the combination of celecoxib has been evaluated with exemestane. Exemestane and 197 
anastrozole, both well known and thoroughly studied third generation aromatase inhibitors, do have 198 
distinct ways of action. Anastrozole, as well as letrozole, is a reversible nonsteroidal inhibitor; 199 
whereas exemestane is an irreversible steroidal inhibitor (Geisler 2011). Maybe it is on this difference 200 
where it resides the contrasting results we have obtained. 201 
Furthermore, we have performed this study using the mentioned mouse model of endometriosis and it 202 
has to be considered the possibility that women’s endometrium might not have the same response to 203 
the treatment with these compounds. The tissue implanted in the mouse peritoneum in this particular 204 
model consists not only of endometrial cells but it also contains myometrial tissue, this is not the case 205 
in the endometriotic lesions developed in women. Moreover, women’s endometriotic lesions are 206 
exposed to the natural hormonal fluctuations due to the menstrual cycle rather than the much shorter 207 
and more rapidly changing estrous cycle of the mouse, which may further affect the tissue developing 208 
in the peritoneal cavity. Further studies should be held in humans as to being able to state the certainty 209 
of the results here presented. This is an approach and a modelization of a very complicated human 210 
disease and the results should be interpreted in this sense. Nevertheless, this is a well established and 211 
accepted model of endometriosis which has been thoroughly used not only in our laboratory (Bilotas 212 
et al. 2010, Olivares et al. 2011, Ricci et al. 2011) but by other investigators too (Fang et al. 2002, 213 
Becker et al. 2006, Grummer 2006, Pelch et al. 2010). 214 
To the best of our knowledge this is the first study to investigate the combination of these two 215 
compounds in endometriosis research. More studies should be addressed to study the pharmacology 216 
of these compounds as to evaluate if they might be having antagonizing effects. In the light of the 217 
results presented, it may be a possibility. Our previous and present works have undoubtedly 218 
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demonstrated the efficacy of celecoxib and anastrozole as monotherapies; and although theoretically 219 
their combination should benefit the patient, we cannot state it so far. 220 
 221 
Materials and Methods 222 
Animals 223 
In this study, 40 two months old female BALB/c mice were used. All procedures were performed 224 
according to NIH Guidelines for the Care and Use of Laboratory Animals and approved by the Ethics 225 
and Research Committee from the Instituto de Biología y Medicina Experimental (IBYME, Buenos 226 
Aires, Argentina). A total of six animals died or were sacrificed between 2-3 after surgery because 227 
they did not fully recover from the procedure. 228 
  229 
Surgical induction of endometriosis and treatment 230 
Endometriosis-like lesions were induced through transplantation of one of the uterine horns to the 231 
bowel mesentery as previously described (Bilotas et al. 2010, Olivares et al. 2011, Ricci et al. 2011). 232 
Briefly, animals were deeply anaesthetized with an intraperitoneal injection of ketamine (100mg/kg) 233 
(Holliday Scott, Buenos Aires, Argentina) and xylazine (10mg/kg) (Richmond, Buenos Aires, 234 
Argentina). Mice underwent laparotomy by midventral incision to expose the uterus and intestine. The 235 
right uterine horn was removed, opened longitudinally and cut into square pieces measuring 236 
approximately 4mm2. Three equal pieces of tissue were then sutured onto serosal layer with a single 237 
6-0 nylon suture (Supralon, Ethicon, NJ, USA) with endometrial tissue facing the serosa. The 238 
abdomen was then closed with a 5-0 nylon suture. 239 
Animals were assigned into four different treatment groups: Control: 150µl vehicle; Celecoxib: 240 
1500ppm of celecoxib (Pfizer, USA) in chow (+ 150µl vehicle); Anastrozole (0.5mg/kg subcutaneous 241 
injection, anastrozole was reconstituted in physiological solution) (AztraZeneca, London, UK) and 242 
Celecoxib + Anastrozole, received the treatments combined. All treatments were administered daily, 243 
started in post-operative day 1 and continued during 28 days. The amount of celecoxib consumed by 244 
each animal was estimated weighing the chow one day and the next, this difference was divided by 245 
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the number of animals per cage; the chow was replaced and weighed every day. Each animal 246 
consumed 4.65 ± 0.17 mg of celecoxib per day. No evidence of toxicity was noted at the doses 247 
administered based on body weight, food consumption, grooming behavior or activity levels 248 
compared with controls. 249 
  250 
Endometriotic like lesions evaluation 251 
After 4 weeks of treatment, animals were sacrificed by cervical dislocation. The abdomen was opened 252 
by ventral midline incision. Implantation sites were localized by the presence of a lesion or by suture 253 
alone. Lesions were counted and measured for volume determination using the formula: V = 254 
(4/3)πr
2
R (where r and R are the radiuses, r < R) (Brodie et al. 2003). Then lesions were excised, fixed 255 
and paraffin-embedded. Specimens were cut into 5µm serial sections. Four to five non-contiguous 256 
sections from each specimen were stained with haematoxylin-eosin and examined microscopically for 257 
the presence of histological hallmarks (glands and stroma) of endometriosis. 258 
 259 
Immunohistochemistry for PCNA, CD34 and COX-2 260 
Serial sections of endometriotic lesions were subjected to standard immunohistochemistry. Tissue 261 
sections were incubated overnight with the primary antibody (rabbit anti-mouse PCNA polyclonal, 262 
1:300, FL-261, Santa Cruz Biotechnology, CA, USA; rat anti-mouse CD34 monoclonal, 1:50, ab8158 263 
Abcam, MA, USA; or rabbit anti-COX-2 polyclonal, 1:200, sc-1747, Santa Cruz Biotechnology) at 264 
4⁰C. After that, sections were treated for 60 min with the corresponding secondary biotinylated 265 
antibody (goat anti-rabbit IgG, 1:200, B7389; or goat anti-rat IgG 1:500, B7139; both from Sigma-266 
Aldrich, MO, USA) followed by incubation with streptavidin-peroxidase (LSAB+ System, Dako, 267 
Carpinteria CA, USA). Binding was visualized incubating sections with DAB and lightly 268 
counterstaining with haematoxylin, prior to permanent mounting.  269 
The number of cells expressing immunoreactivity for PCNA was established using a standard light 270 
microscope. A total of 300 epithelial cells were counted and the percentage of PCNA positive cells 271 
was calculated. Any nuclear staining was regarded as positive. 272 
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For determining the percentage of vascularized area lesions were analyzed with ImageJ 1.33u 273 
software (NIH). The area positive for CD34 was visualized and marked or delimited by the usage of 274 
this software. For each animal evaluated, ten fields were micrographed; for each micrograph all 275 
positive area/s were delimited, added and then divided by the total area of the micrograph, obtaining a 276 
percentage of vascularized area per micrograph. This process was done for every set of ten 277 
micrographs per animal. Then the media for the ten micrographs was calculated, obtaining the media 278 
percentage of vascularized area per animal and the media per treatment was calculated (Olivares et al. 279 
2011, Ricci et al. 2011). 280 
A semiquantitative analysis of cells expressing COX-2 immunoreactivty was done using a standard 281 
light microscope. Briefly, slides were evaluated blinded to treatment by two independent observers. 282 
Ten fields were evaluated, overall staining was recorded (0, absence of staining; 1, mild staining; 2, 283 
moderate staining; 3, marked). 284 
 285 
TUNEL assay 286 
For apoptosis quantification, sections were processed for in-situ immunohistochemical localization of 287 
nuclei exhibiting DNA fragmentation using the apoptosis detection kit Apoptag Plus (Chemicon 288 
International, CA, USA). Sections were treated according to the manufacturer's instructions as 289 
previously described (Meresman et al. 2000). The number of cells positive for TUNEL stain was 290 
established using a standard light microscope at 400X magnification. A total of 300 epithelial cells 291 
were counted and the percentage of TUNEL positive cells was calculated.  292 
 293 
Statistical analysis 294 
Statistical analyses were performed using GraphPad Instat V4.0 software (for Windows, GraphPad 295 
Software, CA, USA). Statistical comparisons between groups were performed using non parametric 296 
Kruskal-Wallis test with Dunn’s multiple comparison post test. Results were expressed as median 297 
(minimum-maximum) or as mean ± S.E.M. In all cases, statistical significance was considered when 298 
p<0.05. 299 
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Figure 1 447 
Celecoxib reduces the number and size of established lesions. Mice underwent surgery for 448 
endometriosis induction. After 28 days of treatment with vehicle, celecoxib, anastrozole or both drugs 449 
simultaneously, mice were sacrificed and the number of lesions established was counted and 450 
measured. A- Celecoxib significantly reduced the mean number of lesions established per mouse. 451 
Scatter plot for lesion establishment; median, minimum and maximum are shown. Control: 2 (1-3); 452 
Celecoxib: 0 (0-2); Anastrozole: 2 (0-3); Anas + Cele: 2 (0-2). B- Celecoxib had a significant effect 453 
reducing endometriotic like lesion size. Scatter plot for the development of lesions in each group; 454 
median, minimum and maximum are shown. Control: 7.238 (2.832-32.28); Celecoxib: 0 (0-8.588); 455 
Anastrozole: 4.177 (0-25.21); Anas + Cele: 7.574 (0-16.49). n = 9 (Control), 10 (Celecoxib), 8 456 
(Anastrozole), 7 (Anas + Cele). *p<0.05 vs. Control group; **p<0.01 vs. Control group. 457 
 458 
Figure 2 459 
Effect of celecoxib and anastrozole on endometriotic-like lesion development. Mice underwent 460 
surgery for endometriosis induction. After 28 days of treatment with vehicle, celecoxib, anastrozole or 461 
both drugs simultaneously, mice were sacrificed and implants were removed and fixed. Cell 462 
proliferation within the implants was evaluated by immunohistochemistry of PCNA. Apoptosis was 463 
evaluated by TUNEL technique. 464 
Left panels: A- After treatment with celecoxib or anastrozole separately epithelial cell proliferation 465 
was significantly diminished compared to control mice. B- After treatment with celecoxib or 466 
anastrozole separately epithelial cell apoptosis was enhanced compared to Control group. Results are 467 
expressed as mean ± SEM. *p<0.05 vs. Control group. n = 5 for all groups. 468 
Right panels Representative micrographs of (A) PCNA and (B) TUNEL staining. (i) Control group, 469 
(ii) Celecoxib group, (iii) Anastrozole group, (iv) Celecoxib + Anastrozole group. Insets: negative 470 
controls, an immunoglobulin of the same immunoglobulin class and concentration as the primary 471 
antibody was used for PCNA immunohistochemistry and sectios were incubated in absence of TdT 472 
enzyme for TUNEL. Magnification 400X. 473 
 474 
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Figure 3 475 
Effect of celecoxib on endometriotic-like lesion vascular density. Mice underwent surgery for 476 
endometriosis induction. After 28 days of treatment with vehicle, celecoxib, anastrozole or both drugs 477 
simultaneously, mice were sacrificed and implants were removed and fixed. Vascular density within 478 
the implants was evaluated performing immunohistochemistry of CD34. Left panel: After treatment 479 
with celecoxib vascular density was diminished compared to control mice. Results are expressed as 480 
mean ± SEM. *p<0.05 vs. Control group. n = 5 for all groups. Right panel: Representative 481 
micrographs of CD34 staining. (i) Control group, (ii) Celecoxib group, (iii) Anastrozole group, (iv) 482 
Celecoxib + Anastrozole group. Inset: negative control, an immunoglobulin of the same 483 
immunoglobulin class and concentration as the primary antibody was used. Magnification 400X. 484 
 485 
Figure 4 486 
Effect of celecoxib and anastrozole on COX-2 immunoreactivity. Mice underwent surgery for 487 
endometriosis induction. After 28 days of treatment with vehicle, celecoxib, anastrozole or both drugs 488 
simultaneously, mice were sacrificed and implants were removed and fixed. COX-2 expression was 489 
evaluated performing immunohistochemistry. Left panel: Semiquantification of the immunostaining 490 
of COX-2 in the developed lesions. When treated with celecoxib COX-2 immunostaining showed a 491 
tendency to be enhanced; with anastrozole, reduced; and when combined, it seemed unaltered; in all 492 
cases compared to control mice. Results are expressed as mean ± SEM. p>0.05 vs. Control group. n = 493 
5 for all groups. Right panel: Representative micrographs of COX-2 staining. (i) Control group, (ii) 494 
Celecoxib group, (iii) Anastrozole group, (iv) Celecoxib + Anastrozole group. Inset: negative control, 495 
an immunoglobulin of the same immunoglobulin class and concentration as the primary antibody was 496 
used. Magnification 400X. 497 
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